New shot could help diabetics shed pounds on top of existing meds
NCT ID NCT06851858
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 study tests an experimental drug called AZD6234, given as a weekly injection, for weight loss in adults with overweight or obesity and type 2 diabetes. Participants are already on a stable dose of a GLP-1 medication. The study will compare AZD6234 to a placebo over 26 weeks to see if it leads to greater weight loss. About 69 people will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AZD6234 (weekly injection)
What this could lead to
If it works, this could offer a new option for weight loss in people with type 2 diabetes who are already on a GLP-1 medication.
What could go wrong
This is a small, early Phase 2 trial. It may not show enough benefit or could have side effects. Success in this study does not guarantee approval.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Birmingham, Alabama, 35205, United States
-
Research Site
Mobile, Alabama, 36608, United States
-
Research Site
Doral, Florida, 33166, United States
-
Research Site
Jacksonville, Florida, 32216, United States
-
Research Site
Miami, Florida, 33135, United States
-
Research Site
Miami, Florida, 33136, United States
-
Research Site
Winter Park, Florida, 32789, United States
-
Research Site
Canton, Georgia, 30114, United States
-
Research Site
Fayetteville, Georgia, 30214, United States
-
Research Site
Chicago, Illinois, 60640, United States
-
Research Site
Oak Brook, Illinois, 60523, United States
-
Research Site
Newton, Kansas, 67114, United States
-
Research Site
Lexington, Kentucky, 40509, United States
-
Research Site
Kansas City, Missouri, 64114, United States
-
Research Site
Las Vegas, Nevada, 89119, United States
-
Research Site
Norman, Oklahoma, 73069, United States
-
Research Site
Knoxville, Tennessee, 37909, United States
-
Research Site
San Antonio, Texas, 78229, United States